Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: A randomized trial

摘要: Background & Aims Early menopause in women with chronic hepatitis C virus (HCV) infection is associated a low likelihood of sustained virological response (SVR) conjunction their antiviral treatment. This potentially related to reduced estrogen secretion. The study was done determine whether selective receptor modulator administration might improve the efficacy current standard care (SOC) treatment, pegylated interferon (PegIFN) α2a plus ribavirin (RBV), for postmenopausal women. Methods One hundred and twenty-three genotype 1b were randomly assigned one two treatment groups: raloxifene hydrochloride (RLX) (60mg/day) SOC (PegIFNα2a 180μg/week RBV 600–1000mg/day) (n=62) or only (n=61). Genotyping performed polymorphism interleukin-28B ( IL28B ) gene region (rs8099917) DNA collected from each patient. Results RLX-treated patient discontinued RLX because systemic rash following 2weeks Twenty-four weeks after SVR rate significantly higher patients (61.3%) than (34.4%) p =0.0051). Further, TT (72.5%) (39.2%) =0.0014), but no such relationship observed carrying minor allele. Conclusions improved C. shows promise as an adjuvant patients.